Yoichiro Moriya

1.9k total citations
49 papers, 1.6k citations indexed

About

Yoichiro Moriya is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Yoichiro Moriya has authored 49 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Yoichiro Moriya's work include Immune Response and Inflammation (14 papers), HER2/EGFR in Cancer Research (10 papers) and Immune Cell Function and Interaction (10 papers). Yoichiro Moriya is often cited by papers focused on Immune Response and Inflammation (14 papers), HER2/EGFR in Cancer Research (10 papers) and Immune Cell Function and Interaction (10 papers). Yoichiro Moriya collaborates with scholars based in Japan and United States. Yoichiro Moriya's co-authors include Masahiko Mihara, Tadamitsu Kishimoto, Motoo Saito, Y Ohsugi, Kaori Fujimoto-Ouchi, Yoshiyuki Ohsugi, Mitsunobu Sato, Yasuhisa Takeda, Kazushige Mori and Nobuhiro Takagi and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer Research and Journal of Virology.

In The Last Decade

Yoichiro Moriya

49 papers receiving 1.5k citations

Peers

Yoichiro Moriya

ONCOL

IMMUN

PRM

RHEUM

Marshall D. Behrens United States

Patrizia Leone Italy

Takeshi Shimaoka Japan

Philip L. Simonian United States

Ori Wald Israel

Henri Montaudié France

Zengbiao Qi United States

Jennifer H. Cox Canada

Michael Willmann Austria

John B. Mumm United States

Marshall D. Behrens United States

Yoichiro Moriya

1.0k ×1.5

ONCOL

1.0k ×1.5

IMMUN

646 ×1.8

128 ×0.5

PRM

182 ×0.8

RHEUM

Citations per year, relative to Yoichiro Moriya Yoichiro Moriya (= 1×) peers Marshall D. Behrens

Countries citing papers authored by Yoichiro Moriya

Since Specialization

Citations

This map shows the geographic impact of Yoichiro Moriya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoichiro Moriya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoichiro Moriya more than expected).

Fields of papers citing papers by Yoichiro Moriya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoichiro Moriya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoichiro Moriya. The network helps show where Yoichiro Moriya may publish in the future.

Co-authorship network of co-authors of Yoichiro Moriya

This figure shows the co-authorship network connecting the top 25 collaborators of Yoichiro Moriya. A scholar is included among the top collaborators of Yoichiro Moriya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoichiro Moriya. Yoichiro Moriya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamashita‐Kashima, Yoriko, et al.. (2017). Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model. Oncology Letters. 14(4). 4197–4205. 21 indexed citations

Furugaki, Koh, Toshiki Iwai, Yoichiro Moriya, Naoki Harada, & Kaori Fujimoto-Ouchi. (2013). Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells. Lung Cancer. 83(1). 44–50. 21 indexed citations

Moriya, Yoichiro. (2011). Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. Oncology Reports. 27(2). 303–10. 12 indexed citations

Iwai, Toshiki, Yoichiro Moriya, Masatoshi Shirane, Kaori Fujimoto-Ouchi, & Kazushige Mori. (2011). Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncology Reports. 27(4). 923–928. 12 indexed citations

Furugaki, Koh, et al.. (2010). Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncology Letters. 1(2). 231–235. 11 indexed citations

Hashimoto, Masahito, Yutaka Kawamura, Shinji Ijichi, et al.. (2008). Enhancement of antitumor activity of OK-432 (Picibanil) by Triton X-114 phase partitioning. International Immunopharmacology. 8(1). 12–19. 2 indexed citations

Fujimoto-Ouchi, Kaori, Fumiko Sekiguchi, Hideyuki Yasuno, et al.. (2006). Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemotherapy and Pharmacology. 59(6). 795–805. 163 indexed citations

Oshikawa, Tetsuya, Masato Okamoto, Tomoyuki Tano, et al.. (2006). Antitumor Effect of OK-432–Derived DNA. Journal of Immunotherapy. 29(2). 143–150. 21 indexed citations

Iyoda, Akira, Masaya Baba, Kiyoshi Shibuya, et al.. (2006). Transbronchial Fine Needle Aspiration Cytological Examination: A Useful Tool for Diagnosing Primary Lung Cancer. The Thoracic and Cardiovascular Surgeon. 54(2). 117–119. 9 indexed citations

10.

Okamoto, Masato, Tetsuya Oshikawa, Tomoyuki Tano, et al.. (2005). Mechanism of Anticancer Host Response Induced by OK-432, a Streptococcal Preparation, Mediated by Phagocytosis and Toll-Like Receptor 4 Signaling. Journal of Immunotherapy. 29(1). 78–86. 55 indexed citations

11.

Oshikawa, Tetsuya, Masato Okamoto, Tomoyuki Tano, et al.. (2005). Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent. International Immunopharmacology. 6(5). 764–773. 5 indexed citations

12.

Ahmed, Sharif, Masato Okamoto, Tetsuya Oshikawa, et al.. (2004). Anti-Tumor Effect of an Intratumoral Administration of Dendritic Cells in Combination with TS-1, an Oral Fluoropyrimidine Anti-Cancer Drug, and OK-432, a Streptococcal Immunopotentiator. Journal of Immunotherapy. 27(6). 432–441. 30 indexed citations

13.

Oshikawa, Tetsuya, Masato Okamoto, Go Ohe, et al.. (2003). Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-γ-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction. International Immunopharmacology. 3(5). 643–655. 12 indexed citations

14.

Okamoto, Masahiro, Tetsuya Oshikawa, Go Ohe, et al.. (2003). Involvement of Toll-Like Receptor 4 Signaling in Interferon- Production and Antitumor Effect by Streptococcal Agent OK-432. JNCI Journal of the National Cancer Institute. 95(4). 316–326. 67 indexed citations

15.

Fujino, Akihiro, Yoichiro Moriya, Yasuhide Morikawa, et al.. (2003). A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism. Journal of Pediatric Surgery. 38(12). 1806–1809. 37 indexed citations

16.

Oshikawa, Tetsuya, Go Ohe, Sachiko Furuichi, et al.. (2001). Severe impairment of anti-cancer effect of lipoteichoic acid-related molecule isolated from a penicillin-killed Streptococcus pyogenes in toll-like receptor 4-deficient mice. International Immunopharmacology. 1(9-10). 1789–1795. 36 indexed citations

17.

Mihara, Masahiko, et al.. (1997). Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE). International Journal of Immunopharmacology. 19(2). 67–74. 3 indexed citations

18.

Mihara, Masahiko, et al.. (1996). In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68. Immunopharmacology. 35(1). 41–46. 17 indexed citations

19.

Makino, Tatsuo, et al.. (1993). The effects of a biological response modifier, OK-432, on tumor-induced alterations in the host metabolism. Surgery Today. 23(7). 621–625. 2 indexed citations

20.

Moriya, Yoichiro, et al.. (1991). Analysis of antitumor effects of OK-432 against syngeneic mouse fibrosarcoma: Combination effect of OK-432 and recombinant lymphokines. International Journal of Immunopharmacology. 13(2-3). 205–215. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact